[go: up one dir, main page]

AR071169A1 - Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas - Google Patents

Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas

Info

Publication number
AR071169A1
AR071169A1 ARP090101134A ARP090101134A AR071169A1 AR 071169 A1 AR071169 A1 AR 071169A1 AR P090101134 A ARP090101134 A AR P090101134A AR P090101134 A ARP090101134 A AR P090101134A AR 071169 A1 AR071169 A1 AR 071169A1
Authority
AR
Argentina
Prior art keywords
variants
covalently modified
streptokinase
modified forms
cysteine
Prior art date
Application number
ARP090101134A
Other languages
English (en)
Inventor
Neeraj Maheshwari
Girish Sahni
Shekhar Kumar
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Publication of AR071169A1 publication Critical patent/AR071169A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153Streptokinase
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24029Aureolysin (3.4.24.29)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Mutantes de la estreptoquinasa, sus fragmentos funcionales y sus formas covalentemente modificadas. Se proveen métodos para la preparacion de la proteína activadora de plasminogeno bacteriana, de estreptoquinasa, sus muteínas, variantes de especies y sus formas covalentemente modificadas caracterizadas por presentar propiedades terapéuticas diferentes, tales como mayor estabilidad proteolítica, vidas medias en plasma extendidas, menor inmunorreactividad y mayor especificidad de coágulos de fibrina. El método comprende la incorporacion de residuos adicionales de cisteína o bien la sustitucion de residuos de cisteína por aminoácidos naturales en regiones no esenciales de la proteína, de modo tal que la actividad catalítica de la proteína resultante permanece mayormente inalterada. Estas variantes de cisteína fueron modificadas además por una union covalente a un polímero reactivo con cisteína, tal como polietilenglicol (PEG) o porciones reactivos con sulfhidrilo de un grupo que incluye, fluoroforos, marcas Spin u otros conjugados pequenos. Aquí se proveen conjugados biologicamente activos específicos del sitio de estreptoquinasas y sus variantes covalentemente modificadas. Reivindicacion 1: Un método caracterizado porque es para producir una célula vegetal, una planta o una parte de ésta transgénica con aumento de rendimiento, preferentemente en condiciones de estrés abiotico transitorio y repetitivo en comparacion con una correspondiente célula vegetal, una planta o una parte de ésta de tipo silvestre no transformada mediante el aumento y generacion de la actividad de un fosfoenolpiruvato carboxilquinasa.
ARP090101134A 2008-03-31 2009-03-30 Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas AR071169A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN837DE2008 2008-03-31

Publications (1)

Publication Number Publication Date
AR071169A1 true AR071169A1 (es) 2010-06-02

Family

ID=41136023

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101134A AR071169A1 (es) 2008-03-31 2009-03-30 Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas

Country Status (10)

Country Link
US (3) US8093032B2 (es)
EP (2) EP2274336B1 (es)
CN (2) CN103627690A (es)
AR (1) AR071169A1 (es)
CL (1) CL2009000793A1 (es)
IL (1) IL208391A (es)
MX (1) MX2010010759A (es)
RU (2) RU2542392C2 (es)
TW (1) TW200944218A (es)
WO (1) WO2009122442A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071169A1 (es) * 2008-03-31 2010-06-02 Council Scient Ind Res Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas
NZ589557A (en) * 2008-06-04 2012-08-31 Talecris Biotherapeutics Inc Immobilised streptokinase, method and kit for preparing plasmin
WO2010064132A1 (en) * 2008-12-05 2010-06-10 Council Of Scientific & Industrial Research Mutants of staphylokinase carrying amino and carboxy-terminal extensions for polyethylene glycol conjugation
MX2013001385A (es) 2010-08-05 2013-07-15 Council Scient Ind Res Construcciones de fusion de proteina que tienen propiedades tromboliticas y anticoagulantes.
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017040885A1 (en) * 2015-09-03 2017-03-09 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
US11008370B2 (en) 2015-10-26 2021-05-18 Council Of Scientific & Industrial Research Genetically modified yeast cell and improved process for production of clot-specific streptokinase
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3592850A1 (en) * 2017-03-09 2020-01-15 PreviPharma Consulting GmbH Preparing and use of glu-plasminogen from blood fractions
JP2021509805A (ja) 2017-12-27 2021-04-08 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 顆粒球コロニー刺激因子活性を示すポリペプチド
EP3914277A4 (en) 2019-01-25 2022-10-19 Council of Scientific & Industrial Research Fibrinolytic composition and method of its preparation
CN111184875A (zh) * 2019-12-16 2020-05-22 中国科学院理化技术研究所 一种蛋白质/碳点纳米杂化材料及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0397366A1 (en) * 1989-05-09 1990-11-14 The Board Of Regents Of The University Of Oklahoma Hybrid streptokinases with fibrin binding domains and methods for the synthesis of same
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO1994017411A1 (en) * 1993-01-27 1994-08-04 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
CN1035193C (zh) * 1994-04-04 1997-06-18 上海医科大学 一种制备重组链激酶的方法
US6087332A (en) * 1997-12-23 2000-07-11 Galler; Lawrence Isaac Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
IN190822B (es) * 1998-12-24 2003-08-23 Council Scient Ind Res
AR071169A1 (es) * 2008-03-31 2010-06-02 Council Scient Ind Res Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas

Also Published As

Publication number Publication date
US20150344861A1 (en) 2015-12-03
US8093032B2 (en) 2012-01-10
WO2009122442A8 (en) 2010-11-04
MX2010010759A (es) 2011-03-03
US9695408B2 (en) 2017-07-04
IL208391A0 (en) 2011-02-28
TW200944218A (en) 2009-11-01
RU2013126581A (ru) 2014-12-20
RU2542392C2 (ru) 2015-02-20
US9115210B2 (en) 2015-08-25
CL2009000793A1 (es) 2010-02-05
RU2010144493A (ru) 2012-05-10
EP3124496A1 (en) 2017-02-01
EP2274336A2 (en) 2011-01-19
US20100034804A1 (en) 2010-02-11
CN102089328B (zh) 2016-10-19
CN103627690A (zh) 2014-03-12
US20120213763A1 (en) 2012-08-23
WO2009122442A2 (en) 2009-10-08
EP3124496B1 (en) 2018-10-31
WO2009122442A3 (en) 2011-01-06
CN102089328A (zh) 2011-06-08
IL208391A (en) 2013-03-24
EP2274336B1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
AR071169A1 (es) Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas
BR0312771A (pt) Métodos para usar polinucleotìdeos artificiais e composições destes para reduzir silenciamento de transgene
HRP20141083T1 (hr) Konjugati faktora viii i polimera
AR061787A1 (es) Plantas con caracteristicas realzadas relacionadas con el rendimiento y un metodo para realizar las mismas
BRPI0412125A (pt) molécula de ácido nucleico isolada, polipeptìdeo de fusão, vetor de expressão, método de produzir um polipeptìdeo de fusão de vegf, captador de fator de crescimento de célula endotelial vascular, composição farmacêutica, método de tratar uma doença ou condição que são restabelecidas, melhoradas ou inibidas pela remoção ou inibição do fator de crescimento endotelial vascular, e, artigo de fabricação
AR040446A1 (es) Defensinas de plantas
AR075114A1 (es) Gen de delta-endotoxina axmi-150 y metodos de uso del mismo
CN114410609A (zh) 一种活性提高的Cas蛋白以及应用
AR047142A1 (es) Composiciones de maiz ricas en lisina y metodos de deteccion de las mismas
AR058841A1 (es) Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico
WO2010012760A3 (en) Plants having modified growth characteristics and a method for making the same
AR081303A1 (es) Disminucion del contenido de acidos grasos saturados de semillas vegetales
JP2019006774A (ja) 植物成長促進剤
AR087719A2 (es) Celula de planta transformada, cultivo de tejidos y planta transgenica
UY38259A (es) Novedosas proteínas de cinnamoil-coa reductasa de plantas mutantes
AR071624A1 (es) Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas mediante la expresion de un acido nucleico que codifica dna proteasa especifica de ubiquitina (ubp) de origen vegetal (ej. oryza)
BR0215273A (pt) Proteìnas, genes da ciclopropano ácido graxo sintase de plantas e seus usos
ES2698835T3 (es) Procedimiento para aumentar la biomasa vegetal
ATE273392T1 (de) Nac1- ein pflanzengen, das für einen transkriptionsfaktor kodiert, welcher an der entwicklung der kotyledonen und seitenwurzeln beteiligt ist
Loic Amino acids modification to improve and fine-tune peptide-based hydrogels
BR9914922A (pt) Métodos para reduzir a extensão de degradação de protease de uma proteìna aplicada a ou produzida por uma planta, para inibir o crescimento de um patógeno vegetal e para produzir uma planta, peptìdeo, molécula de ácido nucleico, segmento de ácido nucleico, construção de ácido nucleico, planta transgênica, semente, célula vegetal, e, composição para o uso na proteção de um peptìdeo, polipeptìdeo ou proteìna da degradação da protease.
CN105651888A (zh) 分析环境因素影响氨基酸营养贡献机理的方法
JP6030908B2 (ja) 菌根菌の培養方法、菌根菌の胞子形成促進方法および菌根菌胞子形成促進用組成物
AR050561A1 (es) Proteinas de fusion activadoras del plasminogeno como agentes tromboliticos.
AR063844A1 (es) Generacion de plantas con alteraciones en el contenido de proteinas fibras o aceite

Legal Events

Date Code Title Description
FB Suspension of granting procedure